Allt inom Interim
Nanexa publishes year-end report and Q4 report 2023
NEX-22 clinical trial application submitted, secured funding and tactical priorities for 2024
Nanexa publishes interim report for January – September 2023
Positive clinical and preclinical results, and secured financing with focus on NEX-22 and next steps in partner projects
